Krystal Biotech (KRYS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 May, 2026Opening remarks and agenda
Meeting called to order by Chairman and CEO, with introductions of key officers and instructions for submitting questions during the session.
Secretary confirmed mailing of meeting materials and availability of proxy statement and annual report.
Board and executive committee updates
Two nominees, Krish Krishnan and Christopher Mason, were presented for election as directors to serve until 2029.
Shareholder proposals
Four proposals were presented: election of directors, ratification of KPMG LLP as auditor, approval of executive compensation, and approval of non-employee director compensation policy.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Krystal Biotech
- VYJUVEK revenue rose 30% as pipeline milestones advanced and a $400M buyback was authorized.KRYS
Q3 2026 - Strong revenue growth and late-stage pipeline advances position for continued expansion.KRYS
Corporate presentation - Q2 2026 revenue rose 24% to $119.2M, with 95% gross margin and strong global expansion.KRYS
Q2 2026 - Robust revenue, global expansion, and a deep gene therapy pipeline drive growth and innovation.KRYS
Corporate presentation - Global expansion and pivotal pipeline progress set the stage for a transformative 12-24 months.KRYS
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue and profit surged, with strong margins and major clinical milestones ahead.KRYS
Q1 2026 - KB407 achieved robust, safe CFTR delivery and expression in CF lungs, enabling registrational trials.KRYS
Study Update - KB408 and KB407 show strong safety, efficient lung gene delivery, and support for accelerated development.KRYS
Status Update - KB301 showed durable, meaningful wrinkle reduction and safety, advancing to Phase 2 for décolleté.KRYS
Study Result